{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ASBP"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ASBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","market":"US","secType":"STK","nameCN":"Aspire Biopharma Holdings Inc.","latestPrice":0.3805,"timestamp":1749240000000,"preClose":0.34,"halted":0,"volume":2607601,"hourTrading":{"tag":"盘后","latestPrice":0.381,"preClose":0.3805,"latestTime":"19:59 EDT","volume":148954,"amount":55970.59848,"timestamp":1749254383629},"delay":0,"floatShares":35345600,"shares":49525970,"eps":-0.348055,"marketStatus":"Market Closed","change":0.0405,"latestTime":"06-06 16:00:00 EDT","open":0.3348,"high":0.388,"low":0.33,"amount":943705.8738337801,"amplitude":0.170588,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.348055,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.34,"preHourTrading":{"tag":"盘前","latestPrice":0.3458,"preClose":0.34,"latestTime":"09:28 EDT","volume":45210,"amount":15530.530158,"timestamp":1749216510048},"postHourTrading":{"tag":"盘后","latestPrice":0.381,"preClose":0.3805,"latestTime":"19:59 EDT","volume":148954,"amount":55970.59848,"timestamp":1749254383629},"volumeRatio":0.830301631950549},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASBP\",,,,,undefined,":{"symbol":"ASBP","floatShares":35345600,"roa":"-779.55%","roe":"--","lyrEps":-0.002976,"volumeRatio":0.830301631950549,"shares":49525970,"dividePrice":0,"high":0.388,"amplitude":0.170588,"preClose":0.34,"low":0.33,"week52Low":0.215,"pbRate":"-2.71","week52High":15.8,"institutionHeld":0,"latestPrice":0.3805,"eps":-0.348055,"divideRate":0,"volume":2607601,"delay":0,"ttmEps":-0.348055,"open":0.3348,"prevYearClose":11.5,"prevWeekClose":0.4301,"prevMonthClose":0.4301,"prevQuarterClose":0.5826,"fiveDayClose":0.4301,"twentyDayClose":0.3354,"sixtyDayClose":0.74},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ASBP\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASBP\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541893062","title":"Director Donald G. Fell Reports Acquisition of Common Shares in Aspire Biopharma Holdings Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2541893062","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541893062?lang=en_us&edition=fundamental","pubTime":"2025-06-07 05:01","pubTimestamp":1749243686,"startTime":"0","endTime":"0","summary":"Donald G. Fell, a Director of Aspire Biopharma Holdings Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL3jdsbj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Donald G. Fell Reports Acquisition of Common Shares in Aspire Biopharma Holdings Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2539403168","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2539403168","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539403168?lang=en_us&edition=fundamental","pubTime":"2025-05-29 01:44","pubTimestamp":1748454295,"startTime":"0","endTime":"0","summary":"Spero Therapeutics (SPRO) and GSK (GSK) said Wednesday that a phase 3 trial of tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, including pyelonephritis, met","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4023","LU1829250122.USD","GSK","BK4532","ASBP","BK4588","BK4585","SGN","BK4139","GSK.UK","BK4608","SPRO","BK4007"],"gpt_icon":0},{"id":"2538479472","title":"Aspire Biopharma to Launch Pre-Workout Supplement Buzz Bomb in Q3; Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2538479472","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538479472?lang=en_us&edition=fundamental","pubTime":"2025-05-28 21:18","pubTimestamp":1748438337,"startTime":"0","endTime":"0","summary":"Aspire Biopharma  said Wednesday it expects to launch Buzz Bomb, its sublingual pre-workout supplement, in Q3.The company has started initial production of the new supplement, which features 50mg of caffeine and is designed to support \"sustained energy and mental focus.\"Aspire Biopharma shares were 72% higher in premarket trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2536617618","title":"Aspire Biopharma Initiates Phase 1 Trial for Fast-Acting High-Dose Aspirin Formulation, Aiming for Accelerated FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2536617618","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536617618?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:32","pubTimestamp":1747744338,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc., headquartered in Humacao, Puerto Rico, has announced the dosing of the first patient in its Phase 1 clinical trial for an oral transmucosal fast-acting high-dose aspirin formulation. This trial is a single-center study conducted in the United States to evaluate the safety, pharmacokinetics, and pharmacodynamics of the company's lead therapeutic candidate. The trial involves healthy adult volunteers receiving a sublingual dose of 162.5 mg aspirin powder or granules, compared to control subjects given the same dose of oral aspirin. The primary outcome measure of the study will be plasma acetylsalicylic acid concentration over time. Aspire anticipates disclosing topline data from the trial early in the third quarter of 2025, which could potentially support accelerated approval, pending FDA review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL6B8n76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASBP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ASBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ASBP","date":"2025-06-05","current":-1.120512,"percent":0.863636,"low":-107.647863,"twenty":-45.929755,"median":-36.600273,"eighty":-10.332083,"high":-0.643502,"avg":-33.004394,"sd":20.779467,"marketCap":19071378},"quantilePoints":[{"date":"2025-03-07","current":-61.718107,"twenty":-79.515888,"median":-61.718107,"eighty":-58.474317,"marketCap":40003023},{"date":"2025-03-14","current":-41.62384,"twenty":-63.871064,"median":-57.344015,"eighty":-54.828644,"marketCap":26978783},{"date":"2025-03-21","current":-49.388839,"twenty":-61.718107,"median":-55.259235,"eighty":-45.464716,"marketCap":32011722},{"date":"2025-03-28","current":-47.36506,"twenty":-59.766092,"median":-48.376949,"eighty":-45.613987,"marketCap":30699995},{"date":"2025-04-04","current":-38.75323,"twenty":-56.183571,"median":-46.367595,"eighty":-43.647619,"marketCap":25118177},{"date":"2025-04-11","current":-38.035578,"twenty":-55.34679,"median":-45.929755,"eighty":-40.946376,"marketCap":24653026},{"date":"2025-04-17","current":-39.57853,"twenty":-55.287942,"median":-45.474044,"eighty":-39.546954,"marketCap":25653101},{"date":"2025-04-25","current":-36.428037,"twenty":-53.967461,"median":-44.487272,"eighty":-38.006872,"marketCap":23611087},{"date":"2025-05-02","current":-25.763721,"twenty":-50.875815,"median":-42.879731,"eighty":-36.06634,"marketCap":16698936},{"date":"2025-05-09","current":-24.070062,"twenty":-48.174572,"median":-41.62384,"eighty":-32.456117,"marketCap":15601179},{"date":"2025-05-16","current":-8.64997,"twenty":-47.360753,"median":-40.170558,"eighty":-27.896584,"marketCap":11330354},{"date":"2025-05-23","current":-0.643502,"twenty":-46.76371,"median":-38.75323,"eighty":-25.110657,"marketCap":10952545},{"date":"2025-05-30","current":-1.730761,"twenty":-46.192459,"median":-37.963813,"eighty":-23.557658,"marketCap":29457944},{"date":"2025-06-05","current":-1.120512,"twenty":-45.929755,"median":-36.600273,"eighty":-10.332083,"marketCap":19071378}],"updateTime":1749282313117}}}